Difference between revisions of "Prophylactic bilateral salpingo-oophorectomy"
Jump to navigation
Jump to search
| (One intermediate revision by the same user not shown) | |||
| Line 5: | Line 5: | ||
==Grossing== | ==Grossing== | ||
*Submit ovaries and tubes in total.<ref>{{cite journal |authors=Fedda FA, Euscher ED, Ramalingam P, Malpica A |title=Prophylactic Risk-reducing Hysterectomies and Bilateral Salpingo-oophorectomies in Patients With Lynch Syndrome: A Clinicopathologic Study of 29 Cases and Review of the Literature |journal=Int J Gynecol Pathol |volume=39 |issue=4 |pages=313–320 |date=July 2020 |pmid=31851061 |doi=10.1097/PGP.0000000000000643 |url=}}</ref><ref>{{cite journal |authors=Mingels MJ, Roelofsen T, van der Laak JA, de Hullu JA, van Ham MA, Massuger LF, Bulten J, Bol M |title=Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls |journal=Gynecol Oncol |volume=127 |issue=1 |pages=88–93 |date=October 2012 |pmid=22710074 |doi=10.1016/j.ygyno.2012.06.015 |url=}}</ref> | *Submit ovaries and tubes [[submitted in total|in total]].<ref>{{cite journal |authors=Fedda FA, Euscher ED, Ramalingam P, Malpica A |title=Prophylactic Risk-reducing Hysterectomies and Bilateral Salpingo-oophorectomies in Patients With Lynch Syndrome: A Clinicopathologic Study of 29 Cases and Review of the Literature |journal=Int J Gynecol Pathol |volume=39 |issue=4 |pages=313–320 |date=July 2020 |pmid=31851061 |doi=10.1097/PGP.0000000000000643 |url=}}</ref><ref>{{cite journal |authors=Mingels MJ, Roelofsen T, van der Laak JA, de Hullu JA, van Ham MA, Massuger LF, Bulten J, Bol M |title=Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls |journal=Gynecol Oncol |volume=127 |issue=1 |pages=88–93 |date=October 2012 |pmid=22710074 |doi=10.1016/j.ygyno.2012.06.015 |url=}}</ref> | ||
==Sign out== | ==Sign out== | ||
| Line 18: | Line 18: | ||
*[[Hereditary breast cancer]]. | *[[Hereditary breast cancer]]. | ||
*[[Sectioning and extensively examining of the fimbriated end]] (SEE-FIM). | *[[Sectioning and extensively examining of the fimbriated end]] (SEE-FIM). | ||
*[[Embedded in toto]]. | |||
==References== | ==References== | ||
Latest revision as of 13:47, 17 June 2024
Prophylactic bilateral salpingo-oophorectomy are done to prevent the development of cancer - when there is a genetic predisposition.
General
- The pathology yield in prophylactic bilateral salpingo-oophorectomies is significant but modest; in series of 26 prophylatic surgeries (BRCA1 22 individuals, BRCA2 4 individuals) there were 2 in situ carcinoma and 2 atypical proliferations.[1] All of the pathology was in BRCA1 carriers.
Grossing
Sign out
Fallopian Tubes and Ovaries, Bilateral Salpingo-Oophorectomy: - Benign ovaries and Fallopian tubes. - NEGATIVE for malignancy.
See also
- Ovarian tumours.
- Hereditary breast cancer.
- Sectioning and extensively examining of the fimbriated end (SEE-FIM).
- Embedded in toto.
References
- ↑ Carcangiu, ML.; Radice, P.; Manoukian, S.; Spatti, G.; Gobbo, M.; Pensotti, V.; Crucianelli, R.; Pasini, B. (Jan 2004). "Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers.". Int J Gynecol Pathol 23 (1): 35-40. doi:10.1097/01.pgp.0000101082.35393.84. PMID 14668548.
- ↑ Fedda FA, Euscher ED, Ramalingam P, Malpica A (July 2020). "Prophylactic Risk-reducing Hysterectomies and Bilateral Salpingo-oophorectomies in Patients With Lynch Syndrome: A Clinicopathologic Study of 29 Cases and Review of the Literature". Int J Gynecol Pathol 39 (4): 313–320. doi:10.1097/PGP.0000000000000643. PMID 31851061.
- ↑ Mingels MJ, Roelofsen T, van der Laak JA, de Hullu JA, van Ham MA, Massuger LF, Bulten J, Bol M (October 2012). "Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls". Gynecol Oncol 127 (1): 88–93. doi:10.1016/j.ygyno.2012.06.015. PMID 22710074.